These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37739811)

  • 1. Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment.
    Nguyen Ky M; Duran A; Hasantari I; Bru A; Deloire M; Brochet B; Ruet A; Schmitt N
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37739811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of viral and self-antigens by T
    Paroni M; Maltese V; De Simone M; Ranzani V; Larghi P; Fenoglio C; Pietroboni AM; De Riz MA; Crosti MC; Maglie S; Moro M; Caprioli F; Rossi R; Rossetti G; Galimberti D; Pagani M; Scarpini E; Abrignani S; Geginat J
    J Allergy Clin Immunol; 2017 Sep; 140(3):797-808. PubMed ID: 28237728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential production of interferon-gamma by CD4+ T cells expressing the homing receptor integrin alpha4/beta7.
    Abramson O; Qiu S; Erle DJ
    Immunology; 2001 Jun; 103(2):155-63. PubMed ID: 11412302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
    Kivisäkk P; Healy BC; Viglietta V; Quintana FJ; Hootstein MA; Weiner HL; Khoury SJ
    Neurology; 2009 Jun; 72(22):1922-30. PubMed ID: 19487650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-homing CD4
    Koetzier SC; van Langelaar J; Blok KM; van den Bosch TPP; Wierenga-Wolf AF; Melief MJ; Pol K; Siepman TA; Verjans GMGM; Smolders J; Lubberts E; de Vries HE; van Luijn MM
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33037101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
    Kimura K; Nakamura M; Sato W; Okamoto T; Araki M; Lin Y; Murata M; Takahashi R; Yamamura T
    Neurol Neuroimmunol Neuroinflamm; 2016 Apr; 3(2):e210. PubMed ID: 27006971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
    van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM
    Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
    Burman J; Fransson M; Tötterman TH; Fagius J; Mangsbo SM; Loskog AS
    Immunology; 2013 Oct; 140(2):211-9. PubMed ID: 23721329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4
    Soldati S; Bär A; Vladymyrov M; Glavin D; McGrath JL; Gosselet F; Nishihara H; Goelz S; Engelhardt B
    J Neuroinflammation; 2023 May; 20(1):123. PubMed ID: 37221552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serosal Cavities Contain Two Populations of Innate-like integrin α4
    Yang JI; Park C; Kho I; Lee S; Suh KS; Kim TJ
    Immune Netw; 2017 Dec; 17(6):392-401. PubMed ID: 29302252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Bühler U; Fleischer V; Luessi F; Rezk A; Belikan P; Graetz C; Gollan R; Wolf C; Lutz J; Bar-Or A; Siffrin V; Zipp F
    Mult Scler; 2017 Apr; 23(4):567-576. PubMed ID: 27436357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
    Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH
    Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
    Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
    BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
    Lamb CA; Mansfield JC; Tew GW; Gibbons D; Long AK; Irving P; Diehl L; Eastham-Anderson J; Price MB; O'Boyle G; Jones DEJ; O'Byrne S; Hayday A; Keir ME; Egen JG; Kirby JA
    J Crohns Colitis; 2017 May; 11(5):610-620. PubMed ID: 28453768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis.
    Rossi B; Dusi S; Angelini G; Bani A; Lopez N; Della Bianca V; Pietronigro EC; Zenaro E; Zocco C; Constantin G
    Front Immunol; 2023; 14():1071553. PubMed ID: 37143680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.
    Tanasescu R; Frakich N; Chou IJ; Filippini P; Podda G; Xin G; Muraleedharan R; Jerca O; Onion D; Constantinescu CS
    Neurol Ther; 2023 Dec; 12(6):2041-2052. PubMed ID: 37715885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls.
    Hart AL; Kamm MA; Knight SC; Stagg AJ
    Clin Exp Immunol; 2004 Jan; 135(1):137-45. PubMed ID: 14678275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.